Verhoog L C, Berns E M, Brekelmans C T, Seynaeve C, Meijers-Heijboer E J, Klijn J G
Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
J Clin Oncol. 2000 Nov 1;18(21 Suppl):119S-24S.
Breast cancer in BRCA2 gene mutation carriers differs from BRCA1-associated breast cancer or so-called sporadic breast cancer in clinical features and behavior. These differences may be of importance for the prevention, screening, and ultimately treatment of breast cancer in women with such germline mutations.
We reviewed the few studies that have reported on survival in patients with BRCA2-associated breast cancer. In this article we discuss why family history is no substitute for hereditary breast cancer with regard to studying survival and possible reasons why studies using family history yield contradictory results, why BRCA2-associated breast cancer should be considered a unique entity, and what methodological problems may exist, especially with regard to family-based studies.
Five studies have reported on survival in BRCA2-associated breast cancer. Two studies showed a statistically significant worse survival for BRCA2 patients, but the patients from one of these studies were later claimed to have a trend toward better prognosis when controls were matched for age and year of diagnosis. The other study found that the unfavorable prognosis of BRCA2 patients was, to a great extent, due to a worse stage of the disease at time of diagnosis. The remaining three studies showed no significant effect of germline BRCA2 mutations on survival. The numbers of BRCA2 patients investigated in these studies were 42, 20, 23, 28, and 54 patients. Five-year overall survival in these patients varied from 65% to 74%.
No definite conclusion can be made with regard to the prognosis of BRCA2-associated breast cancer, but large differences in comparison with sporadic breast cancer are not likely to exist. Breast cancer caused by BRCA2 mutations is also a distinct entity with its own features when compared with BRCA1-associated breast cancer. In contrast with BRCA1-associated breast cancer, BRCA2 tumors tend to be more often steroid receptor-positive.
BRCA2基因突变携带者的乳腺癌在临床特征和行为方面不同于BRCA1相关乳腺癌或所谓的散发性乳腺癌。这些差异对于具有此类种系突变的女性乳腺癌的预防、筛查及最终治疗可能具有重要意义。
我们回顾了少数关于BRCA2相关乳腺癌患者生存情况的研究。在本文中,我们讨论了为何在研究生存情况时家族史不能替代遗传性乳腺癌,以及使用家族史的研究产生相互矛盾结果的可能原因,为何BRCA2相关乳腺癌应被视为一个独特的实体,以及可能存在哪些方法学问题,尤其是在基于家族的研究方面。
五项研究报告了BRCA2相关乳腺癌的生存情况。两项研究显示BRCA2患者的生存情况在统计学上显著较差,但其中一项研究中的患者后来声称,在对照按年龄和诊断年份匹配后有预后改善的趋势。另一项研究发现,BRCA2患者的不良预后在很大程度上是由于诊断时疾病分期较差。其余三项研究显示种系BRCA2突变对生存无显著影响。这些研究中调查的BRCA2患者数量分别为42例、20例、23例、28例和54例。这些患者的五年总生存率在65%至74%之间。
关于BRCA2相关乳腺癌的预后尚无明确结论,但与散发性乳腺癌相比不太可能存在巨大差异。与BRCA1相关乳腺癌相比,BRCA2突变导致的乳腺癌也是具有自身特征的独特实体。与BRCA1相关乳腺癌不同,BRCA2肿瘤往往更常为类固醇受体阳性。